Cytek Biosciences, Inc.

Industrials
Biotechnology: Laboratory Analytical Instruments
www.cytekbio.com

Earnings Score
Moat Score
Safety Score

Market Cap $477.42M
PE -79
Debt $1.05M
Cash $98.75M
EV $379.72M
FCF $21.85M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$6.02M
EBIT	-$5.70M
ROE	-2%
ROA	-1%
FCF	$21.85M
Equity	$395.74M
Growth Stability	-639%
PE	-79.3
PEG	2.11K
PB	1.21
P/FCF	21.85
P/S	2.38
Price/Cash	0.21
Debt/Equity	0
Debt/FCF	0.05
Net Margins	-3%
Gross Margins	55%
Op. Margins	-3%
Earnings CAGR	-0%
Sales Growth YoY	-1%
Sales Growth QoQ	12%
Sales CAGR	18%
FCF CAGR	10%
Equity CAGR	-1%
Earnings Stability	-0.72
Earnings Growth YoY	75%
Earnings Growth QoQ	926%

Earnings CAGR 5Y	-0%
Sales CAGR 5Y	18%
FCF CAGR 5Y	10%
Equity CAGR 5Y	-1%
Earnings CAGR 3Y	15%
Sales CAGR 3Y	15%
FCF CAGR 3Y	84%
Equity CAGR 3Y	-3%
Market Cap	$477.42M
Revenue	$200.45M
Assets	$499.50M
Total Debt	$1.05M
Cash	$98.75M
Shares Outstanding	129.21M
EV	379.72M
Earnings Score	6%
Moat Score	13%
Safety Score	67%
Final Score	29%
Working Capital	328.78M
Current Ratio	5.86
Gross Profit	$111.11M
Shares Growth 3y	-2%
Equity Growth QoQ	3%
Equity Growth YoY	1%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.

SEC Filings

Direct access to Cytek Biosciences, Inc. (CTKB) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Cytek Biosciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Cytek Biosciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -0%

Stability -72%

loading chart...

Cytek Biosciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Cytek Biosciences, Inc..

Years

Calculation mode

= $441M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$22M	$24M	$27M	$29M	$32M	$35M	$39M	$43M	$47M	$52M	$57M	$573M
DCF		$22M	$22M	$22M	$22M	$22M	$22M	$22M	$22M	$22M	$22M	$221M
Value	$441M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	3%	0%	2%	-6%	-3%	-3%
ROA	-	2%	0%	-3%	-1%	-1%
ROE	-	0%	1%	-3%	-2%	-2%

Bad Net Margins (-3%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	0	-0.1	2.6	0.05	0.05
Debt over Equity	-	0	0.01	0	0	0
Growth Stability	-	-	-	-639%	-	-639%

Good Debt/FCF ratio (0.05)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-639%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	38%	28%	18%	4%	18%
Earnings YoY growth	-	-100%	-	-589%	-50%	-0%
Equity YoY growth	-	-3K%	5%	-8%	1%	-1%
FCF YoY growth	-	-98%	-8K%	-103%	3K%	10%